{
"id":"mk19_bb_hm_s26",
"subspecialtyId":"hm",
"title":"Deep Venous Thrombosis and Pulmonary Embolism",
"jsonContent":{
"type":"section",
"id":"mk19_bb_hm_s26",
"title":{
"__html":"Deep Venous Thrombosis and Pulmonary Embolism"
},
"titleNode":{
"type":"section-title",
"hlId":"c4d506",
"children":[
"Deep Venous Thrombosis and Pulmonary Embolism"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_hm_s26_1",
"title":{
"__html":"Screening"
},
"titleNode":{
"type":"section-title",
"hlId":"db7551",
"children":[
"Screening"
]
},
"children":[
{
"type":"p",
"hlId":"4b8879",
"children":[
"Routine extensive screening for underlying cancer or thrombophilia in all patients with unprovoked ",
{
"type":"abbreviation",
"title":"venous thromboembolism",
"children":[
"VTE"
]
},
" is not recommended."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_hm_s26_2",
"title":{
"__html":"Prevention"
},
"titleNode":{
"type":"section-title",
"hlId":"c53b76",
"children":[
"Prevention"
]
},
"children":[
{
"type":"p",
"hlId":"96e82e",
"children":[
"Pharmacologic prophylaxis is recommended in most hospitalized patients without a contraindication. VTE prophylaxis with graduated compression stockings is not recommended. In the absence of increased bleeding risk, intermittent pneumatic compression devices are not recommended as the only prophylaxis. ",
{
"type":"alert",
"children":[
"VTE prophylaxis is often only given during a patient's hospitalization with the exception of postdischarge prophylaxis (up to 5 weeks) following hip fracture, hip and knee replacement, and major cancer surgery."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_bb_hm_s26_3",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"541b13",
"children":[
"Use the Wells criteria for ",
{
"type":"abbreviation",
"title":"deep venous thrombosis",
"children":[
"DVT"
]
},
" or ",
{
"type":"abbreviation",
"title":"pulmonary embolism",
"children":[
"PE"
]
},
" scores for all patients."
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"464216",
"children":[
"In patients with low pretest probability for DVT (score ≤1) or PE (score ≤4), obtain a D-dimer blood test."
]
},
" ",
{
"type":"list-item",
"hlId":"e8496e",
"children":[
"If the D-dimer is negative, no further testing is needed."
]
},
" ",
{
"type":"list-item",
"hlId":"a336c0",
"children":[
"If the D-dimer is positive or the Wells score indicates that a DVT or PE is likely (Wells DVT score >1; Wells PE score >4), obtain an imaging study. Duplex ultrasonography and ",
{
"type":"abbreviation",
"title":"computed tomography angiography",
"children":[
"CTA"
]
},
" are the diagnostic tests of choice for DVT and PE, respectively."
]
},
" "
]
},
{
"type":"p",
"hlId":"236a0f",
"children":[
"A PERC (Pulmonary Embolism Rule-Out Criteria) score of zero eliminates the need for D-dimer testing or CTA."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_hm_s26_4",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"482b28",
"children":[
"Hospital admission is unnecessary for most patients with DVT; in selected, stable patients, outpatient therapy can be initiated with apixaban or rivaroxaban."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_bb_hm_s26_inline_t1"
],
"forceOpen":true
},
{
"type":"p",
"hlId":"5a06fb",
"children":[
"Thrombolytic therapy indications:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"40d7e0",
"children":[
"consider for massive DVT leading to impaired venous drainage, severe edema, and acute limb ischemia"
]
},
" ",
{
"type":"list-item",
"hlId":"dc0884",
"children":[
"massive PE and shock from low cardiac output"
]
},
" "
]
},
{
"type":"p",
"hlId":"609488",
"children":[
"Anticoagulant treatment options for VTE include initial parenteral administration of ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"low-molecular-weight heparin",
"children":[
"LMWH"
]
},
","
]
},
" ",
{
"type":"no-wrap",
"children":[
{
"type":"abbreviation",
"title":"unfractionated heparin",
"children":[
"UFH"
]
},
","
]
},
" or fondaparinux, followed by oral administration of dabigatran, edoxaban, or warfarin or monotherapy (oral anticoagulant started without initial parenteral anticoagulant) with apixaban or rivaroxaban. DOACs are preferred to warfarin."
]
},
{
"type":"p",
"hlId":"ff692a",
"children":[
"The only clear indication for an ",
{
"type":"abbreviation",
"title":"inferior vena cava",
"children":[
"IVC"
]
},
" filter is in patients with an acute proximal DVT or an acute PE with an absolute contraindication to anticoagulation."
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"a281dd",
"children":[
"If DVT is diagnosed, a CTA is not needed because the treatment is the same."
]
},
" ",
{
"type":"list-item",
"hlId":"8d281c",
"children":[
"Parenteral anticoagulant administration must overlap with warfarin for at least 5 days and until the ",
{
"type":"abbreviation",
"title":"international normalized ratio",
"children":[
"INR"
]
},
" is >2 for 24 hours."
]
},
" "
]
},
{
"type":"p",
"hlId":"f7aafb",
"children":[
"Warfarin reversal:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"c833ac",
"children":[
"INR 4.5-10 → withhold warfarin"
]
},
" ",
{
"type":"list-item",
"hlId":"2adddd",
"children":[
"INR >10 without bleeding → oral vitamin K"
]
},
" ",
{
"type":"list-item",
"hlId":"6fe6a5",
"children":[
"life-threatening bleeding → vitamin K and ",
{
"type":"abbreviation",
"title":"4-factor prothrombin complex concentrate",
"children":[
"4f-PCC"
]
}
]
},
" "
]
},
{
"type":"p",
"hlId":"196fe4",
"children":[
{
"type":"abbreviation",
"title":"direct oral anticoagulant",
"children":[
"DOAC"
]
},
" life-threatening bleeding reversal:"
]
},
{
"type":"list",
"children":[
" ",
{
"type":"list-item",
"hlId":"34af60",
"children":[
"stop drug"
]
},
" ",
{
"type":"list-item",
"hlId":"157221",
"children":[
"dabigatran → idarucizumab"
]
},
" ",
{
"type":"list-item",
"hlId":"fec216",
"children":[
"apixaban, rivaroxaban, edoxaban → either 4f-PCC or andexanet alfa"
]
},
" "
]
}
]
}
]
},
"tablesContent":{
"mk19_bb_hm_s26_inline_t1":{
"id":"mk19_bb_hm_s26_inline_t1",
"number":1,
"bookId":"hm",
"title":{
"__html":"Study Table: Duration of Anticoagulant Therapy for VTE"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"f248e7",
"children":[
"Study Table: Duration of Anticoagulant Therapy for VTE"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"89e6fe",
"class":"col hd l",
"children":[
"Type of Thrombotic Event"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d712e7",
"class":"col hd l",
"children":[
"Duration of Anticoagulant Therapy",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b01bf7",
"class":"cell txt l",
"children":[
"Superficial vein thrombophlebitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"32f593",
"class":"cell txt l",
"children":[
"No anticoagulation suggested"
]
},
" ",
{
"type":"p",
"hlId":"59d8d8",
"class":"cell txt l",
"children":[
"Treat with supportive care (analgesia, warm compresses, and ",
{
"type":"abbreviation",
"title":"nonsteroidal anti-inflammatory drugs",
"children":[
"NSAIDs"
]
},
") and image if symptoms progress"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfedb5",
"class":"cell txt l",
"children":[
"Superficial vein thrombosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"56c310",
"class":"cell txt l",
"children":[
"Anticoagulate if increased risk for clot progression (e.g., extensive DVT, involvement above knee, severe symptoms, other thrombophilic risk factors)"
]
},
" ",
{
"type":"p",
"hlId":"797178",
"class":"cell txt l",
"children":[
"If not anticoagulated, follow-up in 1 week and image if symptoms are persistent or worsening"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9f993",
"class":"cell txt l",
"children":[
"Distal leg DVT"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cd8564",
"class":"cell txt li",
"children":[
"Provoked or unprovoked, asymptomatic or mild symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ceda35",
"class":"cell txt l",
"children":[
"No anticoagulation suggested in healthy patients, but monitor with serial duplex ultrasonography within 1-2 weeks"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c411c8",
"class":"cell txt li",
"children":[
"Provoked or unprovoked, moderate-severe symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"47fde1",
"class":"cell txt l",
"children":[
"3-6 months"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0adf97",
"class":"cell txt l",
"children":[
"Proximal leg DVT or PE"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f3b45",
"class":"cell txt li",
"children":[
"Provoked (by surgery, trauma, immobility)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"47fde1",
"class":"cell txt l",
"children":[
"3-6 months"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cefc09",
"class":"cell txt li",
"children":[
"Unprovoked"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0cbede",
"class":"cell txt l",
"children":[
"Extended",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e58fa",
"class":"cell txt li",
"children":[
"Recurrent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"51eaca",
"class":"cell txt l",
"children":[
"Duration of therapy depends on whether VTE events were provoked or unprovoked"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"84086e",
"class":"cell txt l",
"children":[
"Upper extremity DVT, proximal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"320b1d",
"class":"cell txt l",
"children":[
"3 months or as long as a central venous catheter remains in place"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f4623c",
"class":"cell txt l",
"children":[
"Cancer-associated DVT or PE"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0bba16",
"class":"cell txt l",
"children":[
"As long as the cancer is active or being treated"
]
},
" ",
{
"type":"p",
"hlId":"323e3c",
"class":"cell txt l",
"children":[
"LMWH or DOACs are the preferred anticoagulants",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"565883",
"class":"cell txt l",
"children":[
"CTEPH"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f23578",
"class":"cell txt l",
"children":[
"Extended"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Decisions regarding duration of anticoagulation must always weigh the risk of VTE recurrence, risk of bleeding, and patient preference."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Indicates long-term anticoagulation therapy with periodic (such as once per year) reevaluation of the risks, benefits, and burdens of long-term therapy and discussion of new clinical study results and new anticoagulant drugs."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38:496-520. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31381464",
"target":"_blank"
},
"children":[
"PMID: 31381464"
]
},
" doi:10.1200/JCO.19.01461"
],
[
"Data from Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693-4738. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33007077",
"target":"_blank"
},
"children":[
"PMID: 33007077"
]
},
" doi:10.1182/bloodadvances.2020001830"
]
]
}
}
}